Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis
Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.

Microscope Shows How Nanoferries Invade Cells
Nanoparticles are just billionths of a millimeter in size. Exhibiting novel and often surprising properties, they are finding their way into an endless stream of equally innovative products. In medical therapies, for example, tiny nanovehicles could one day ferry drugs or even genes into cells. So far, the only way of testing these approaches has been to wait for the desired effect to show - the activation of a transported gene inside a cell for example. Under the direction of LMU Munich physicochemist Professor Christoph Bräuchle, a research group cooperating with Dr. Christian Plank of the Technische Universität MÃønchen (TUM) has now used a highly sensitive microscopic technique to pursue individual nanoparticles as they make their way into target cells - in real-time and at high spatial and temporal resolution. They tested magnetic nanoparticles that could be used, among other things, in cancer therapy. This approach should also allow a better understanding of existing nanovectors as well as the development of new systems, as reported in the current cover story of the Journal of Controlled Release.
News of the day
Team Effort Needed To Report On Science, University Of Alberta Study Says
Trust in science is diminishing, according to recent studies, especially in the area of biomedicine, biotech and genetics. University of Alberta researchers Tim Caulfield and Tania Bubela blame it on the complexity of many discoveries and they"re concerned the whole message from the study isn"t getting across to the general public.
Cardiovascular

One In Four HIV-Positive Women Does Not Undergo Cervical Cancer Screenings, Study Finds

About one in four HIV-positive women in the U.S. does not opt to undergo an annual Pap test for cervical cancer even though they are at an increased risk for the disease, according to a study in the Journal of Acquired Immune Deficiency Syndromes, Reuters reports. For the study, Alexandra Oster and colleagues from the Centers for Disease Control and Prevention analyzed the responses of 2,417 HIV-positive women from 18 states who participated in interviews for the Supplement to HIV/AIDS Surveillance Project.The researchers found that 23% of the women had not undergone a Pap test in the year before the interviews and that older age and a poorly functioning immune system were independent predictors of whether women had Pap tests.They wrote, "The risk of cervical cancer has not decreased since the introduction of (highly active antiretroviral) therapy, highlighting the continued importance of cervical cancer screening in this population." They added that "cervical cancer screening should be a high priority" for HIV-positive women (Reuters, 7/30). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009